Compare Cytokinetics Inc (CYTK) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Quanta Services Inc — how do they compare? Cytokinetics Inc trades at $81.99 (market cap $11.12B), while Quanta Services Inc trades at $663.54 (market cap $99.18B). The key difference: Quanta Services Inc is far larger — about 8.9× Cytokinetics Inc's market cap, and Quanta Services Inc pays a 0.07% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals.
| CYTK | PWR | |
|---|---|---|
Market Cap | $11.12B | $99.18B |
Sector | Technology | Industrials |
52-Week High | $87.26 | $785.24 |
52-Week Low | $33.23 | $372.50 |
Enterprise Value | $11.59B | $105.14B |
Dividend Yield | — | 0.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $82.24, down 3.1% today, with a bullish technical outlook supported by moving averages and RSI near oversold levels. The company shows strong analyst support with 97% buy ratings and a $110.40 consensus target, but faces fundamental challenges with a -784% net income margin and negative cash flow from operations of -$510M in 2025. Recent positive developments include FDA approval and European launch of Myqorzo, driving commercial momentum.
Outlook remains speculative with high valuation (P/S 93.92) against significant losses, yet growth potential exists if Myqorzo gains market traction. Key risks include cash burn, competitive pressure, and reliance on single drug success. Institutional sentiment is overwhelmingly bullish, but investors must weigh high risk-reward profile amid ongoing profitability challenges.
Quanta Services (PWR) trades at $646.70, down 1.8% with a bearish technical signal despite strong fundamentals. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 results pending. Revenue growth remains robust, climbing from $17.1B in 2022 to $28.5B in 2025, though net margins are thin at 3.67%. Analyst consensus is strongly bullish with a $836.80 price target, representing 29% upside potential from current levels.
PWR offers exposure to infrastructure spending tailwinds from AI data centers and grid modernization, but faces valuation concerns with a P/E of 88.7. The stock's premium multiple requires flawless execution amid aggressive capital expenditure plans. Near-term technical weakness contrasts with strong institutional support and positive earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
